Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Novan Inc's Business Segments
Novan Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2023
Reportable Segments
2
Largest Segment
Commercial Operations
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2023
- Commercial Operations74.2%
- Research and Development Operations25.8%
Revenue by Reportable Segment - Q1 FY2023
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Commercial Operations | $ 2 | 74.2% |
| Research and Development Operations | $ 1 | 25.8% |
Revenue by Product & Service Category - Q1 FY2023
- Product76.2%
- Rhofade34.7%
- License and Collaboration18.5%
- Wynzora16.8%
- Minolira10.9%
- Cloderm6.9%
- Manufactured Product, Other6.9%
- Grant5.4%
Revenue by Product & Service Category - Q1 FY2023
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 2 | 76.2% |
| Rhofade | $ 1 | 34.7% |
| License and Collaboration | $ 1 | 18.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
5 more categories available
Sign in to unlock the full Novan Inc dataset.
Description of Novan Inc
Novan Inc. is a pharmaceutical company headquartered in Morrisville, North Carolina. Novan focuses on the development and commercialization of innovative therapies to address unmet needs in dermatology and infectious diseases. The company was founded in 2006 and has since become a leader in topical nitric oxide-based therapies.
One of Novan's main areas of expertise is the use of nitric oxide (NO) in dermatology. Nitric oxide is a naturally occurring molecule in the human body that plays a crucial role in various physiological processes, including immune response, wound healing, and blood flow regulation. Novan has developed a proprietary platform called Nitricil, which harnesses the therapeutic potential of nitric oxide for various dermatological conditions.
Novan's flagship product is SB206, a topical gel for the treatment of molluscum contagiosum. Molluscum contagiosum is a common viral skin infection that primarily affects children and immunocompromised individuals. SB206 has shown promising results in clinical trials, demonstrating rapid and effective clearance of molluscum lesions with no significant side effects.
In addition to molluscum contagiosum, Novan is also developing other nitric oxide-based therapies for various dermatological conditions. These include SB204 for the treatment of acne vulgaris and SB414 for the treatment of atopic dermatitis. These conditions have a significant impact on patients' quality of life, and Novan aims to provide safe and effective therapies to alleviate the associated symptoms.
Apart from dermatology, Novan has expanded its focus to infectious diseases, particularly viral infections. The company has developed a new class of antiviral drugs called NITRICILs that utilize nitric oxide to inhibit the replication of various viruses, including coronaviruses. Novan's lead candidate in this area is NVN410, which has demonstrated potent antiviral activity against SARS-CoV-2, the virus responsible for COVID-19.
Novan has a strong commitment to research and development, with a diverse pipeline of potential therapies in various stages of development. The company collaborates with leading academic institutions, government agencies, and other pharmaceutical companies to advance its research and bring innovative treatments to patients.
In terms of manufacturing and commercialization, Novan has established strategic partnerships and collaborations with contract manufacturing organizations and other pharmaceutical companies to ensure the efficient production and distribution of its products. The company also emphasizes cost-effective solutions to make its therapies accessible and affordable to patients.
Overall, Novan Inc. is a biopharmaceutical company at the forefront of nitric oxide-based therapies for dermatological conditions and infectious diseases. With its cutting-edge research, innovative products, and commitment to patient care, Novan strives to make a significant impact in improving the lives of millions of people around the world.
One of Novan's main areas of expertise is the use of nitric oxide (NO) in dermatology. Nitric oxide is a naturally occurring molecule in the human body that plays a crucial role in various physiological processes, including immune response, wound healing, and blood flow regulation. Novan has developed a proprietary platform called Nitricil, which harnesses the therapeutic potential of nitric oxide for various dermatological conditions.
Novan's flagship product is SB206, a topical gel for the treatment of molluscum contagiosum. Molluscum contagiosum is a common viral skin infection that primarily affects children and immunocompromised individuals. SB206 has shown promising results in clinical trials, demonstrating rapid and effective clearance of molluscum lesions with no significant side effects.
In addition to molluscum contagiosum, Novan is also developing other nitric oxide-based therapies for various dermatological conditions. These include SB204 for the treatment of acne vulgaris and SB414 for the treatment of atopic dermatitis. These conditions have a significant impact on patients' quality of life, and Novan aims to provide safe and effective therapies to alleviate the associated symptoms.
Apart from dermatology, Novan has expanded its focus to infectious diseases, particularly viral infections. The company has developed a new class of antiviral drugs called NITRICILs that utilize nitric oxide to inhibit the replication of various viruses, including coronaviruses. Novan's lead candidate in this area is NVN410, which has demonstrated potent antiviral activity against SARS-CoV-2, the virus responsible for COVID-19.
Novan has a strong commitment to research and development, with a diverse pipeline of potential therapies in various stages of development. The company collaborates with leading academic institutions, government agencies, and other pharmaceutical companies to advance its research and bring innovative treatments to patients.
In terms of manufacturing and commercialization, Novan has established strategic partnerships and collaborations with contract manufacturing organizations and other pharmaceutical companies to ensure the efficient production and distribution of its products. The company also emphasizes cost-effective solutions to make its therapies accessible and affordable to patients.
Overall, Novan Inc. is a biopharmaceutical company at the forefront of nitric oxide-based therapies for dermatological conditions and infectious diseases. With its cutting-edge research, innovative products, and commitment to patient care, Novan strives to make a significant impact in improving the lives of millions of people around the world.
Novan Inc. is a biotechnology company focused on developing innovative treatments primarily in dermatology. The company uses its proprietary nitric oxide (NO) platform to create therapeutic products targeting a variety of skin conditions and diseases. Below is an extensive description of the segments, products, and services that Novan Inc. offers:
Segments
1. Dermatology:
- Novan targets a variety of dermatological conditions through its research and product development efforts. This segment encompasses multiple skin diseases, including acne, psoriasis, and skin infections. The goal is to offer solutions that alleviate symptoms and improve the quality of life for patients.
2. Therapeutic Development:
- The company focuses on the development of novel therapeutics that utilize nitric oxide, which can help reduce inflammation, promote healing, and combat microbial infections. This segment emphasizes the innovative nature of the treatments, bridging basic research and clinical application.
3. Clinical Research:
- Novan is heavily invested in clinical trials and research studies to evaluate the efficacy and safety of its products. This includes both pre-clinical and clinical stages of drug development. Their commitment to evidence-based research is a significant aspect of their operational strategy.
Products
1. Nitric Oxide Donor Products:
- One of Novans core product offerings is centered around nitric oxide delivery systems. These products can provide localized treatment for various skin conditions harnessing the therapeutic properties of nitric oxide.
2. SB206:
- This is a topical gel formulation for the treatment of viral infections, specifically focusing on the treatment of common warts. SB206 has been studied for its efficacy in eradicating wart-inducing viruses.
3. SB414:
- Another product in development, SB414 is aimed at treating atopic dermatitis. This formulation seeks to leverage the anti-inflammatory properties of nitric oxide to provide relief from the symptoms associated with this chronic skin condition.
4. SB208:
- Targeted at acne treatment, this product is in various stages of development and represents Novans commitment to addressing widespread dermatological issues through innovative therapeutic solutions.
5. Pipeline Products:
- Novan has several pipeline products in various stages of research and development, focusing on additional applications of nitric oxide in dermatology and beyond. These products aim to cater to unmet medical needs in chronic skin conditions and infections.
Services
1. Clinical Trial Management:
- Novan offers comprehensive management of clinical trials, including study design, implementation, data management, and regulatory compliance. This service ensures that their products are thoroughly tested and validated before market entry.
2. Regulatory Support:
- The company provides support for navigating the complex regulatory frameworks associated with drug development and approval. This includes interactions with regulatory agencies such as the FDA to facilitate the approval process for new therapeutics.
3. Collaborative Research Programs:
- Novan engages in partnerships with academic institutions and other research organizations to further explore the potential applications of their nitric oxide platform. These collaborations enhance the companys research capabilities and broaden the scope of its product development.
4. Patient Education and Support:
- Understanding the importance of patient involvement, Novan develops educational resources to help patients understand their conditions and the benefits of available treatments. Support programs may also be available to assist patients during their treatment journey.
5. Intellectual Property Management:
- The company actively manages its patent portfolio to protect its innovative technologies and therapeutic approaches. This strategic focus on intellectual property is crucial for maintaining a competitive advantage in the biotechnology sector.
In summary, Novan Inc. operates in the biotechnology space with a strong emphasis on dermatological therapeutics, using its proprietary nitric oxide technology to develop a range of products aimed at treating various skin conditions. The company is committed to robust clinical research, regulatory excellence, and patient support, positioning it as a key player in the field of dermatology.
Segments
1. Dermatology:
- Novan targets a variety of dermatological conditions through its research and product development efforts. This segment encompasses multiple skin diseases, including acne, psoriasis, and skin infections. The goal is to offer solutions that alleviate symptoms and improve the quality of life for patients.
2. Therapeutic Development:
- The company focuses on the development of novel therapeutics that utilize nitric oxide, which can help reduce inflammation, promote healing, and combat microbial infections. This segment emphasizes the innovative nature of the treatments, bridging basic research and clinical application.
3. Clinical Research:
- Novan is heavily invested in clinical trials and research studies to evaluate the efficacy and safety of its products. This includes both pre-clinical and clinical stages of drug development. Their commitment to evidence-based research is a significant aspect of their operational strategy.
Products
1. Nitric Oxide Donor Products:
- One of Novans core product offerings is centered around nitric oxide delivery systems. These products can provide localized treatment for various skin conditions harnessing the therapeutic properties of nitric oxide.
2. SB206:
- This is a topical gel formulation for the treatment of viral infections, specifically focusing on the treatment of common warts. SB206 has been studied for its efficacy in eradicating wart-inducing viruses.
3. SB414:
- Another product in development, SB414 is aimed at treating atopic dermatitis. This formulation seeks to leverage the anti-inflammatory properties of nitric oxide to provide relief from the symptoms associated with this chronic skin condition.
4. SB208:
- Targeted at acne treatment, this product is in various stages of development and represents Novans commitment to addressing widespread dermatological issues through innovative therapeutic solutions.
5. Pipeline Products:
- Novan has several pipeline products in various stages of research and development, focusing on additional applications of nitric oxide in dermatology and beyond. These products aim to cater to unmet medical needs in chronic skin conditions and infections.
Services
1. Clinical Trial Management:
- Novan offers comprehensive management of clinical trials, including study design, implementation, data management, and regulatory compliance. This service ensures that their products are thoroughly tested and validated before market entry.
2. Regulatory Support:
- The company provides support for navigating the complex regulatory frameworks associated with drug development and approval. This includes interactions with regulatory agencies such as the FDA to facilitate the approval process for new therapeutics.
3. Collaborative Research Programs:
- Novan engages in partnerships with academic institutions and other research organizations to further explore the potential applications of their nitric oxide platform. These collaborations enhance the companys research capabilities and broaden the scope of its product development.
4. Patient Education and Support:
- Understanding the importance of patient involvement, Novan develops educational resources to help patients understand their conditions and the benefits of available treatments. Support programs may also be available to assist patients during their treatment journey.
5. Intellectual Property Management:
- The company actively manages its patent portfolio to protect its innovative technologies and therapeutic approaches. This strategic focus on intellectual property is crucial for maintaining a competitive advantage in the biotechnology sector.
In summary, Novan Inc. operates in the biotechnology space with a strong emphasis on dermatological therapeutics, using its proprietary nitric oxide technology to develop a range of products aimed at treating various skin conditions. The company is committed to robust clinical research, regulatory excellence, and patient support, positioning it as a key player in the field of dermatology.